Resistance | All isolates | Sampled clinical cases | |||
---|---|---|---|---|---|
Total | CABSI | HABSI | P valuea | ||
Any extended spectrum cephalosporin | 72/131 (55.0%) | 45/74 (60.8%) | 39/65 (60%) | 6/9 (66.7%) | 1 |
ESBL production | 50/111 (45%) | 33/61 (54.1%) | 28/52 (53.8%) | 5/9 (55.6%) | 1 |
Others | 22/131 (16.8%) | 12/74 (16.2%) | 11/65 (16.9%) | 1/9 (11.1%) | 1 |
Any carbapenem | 1/130 (0.8%) | 0/73 (0.0%) | 0/64 (0.0%) | 0/9 (0.0%) | - |
Any aminoglycoside | 30/129 (23.3%) | 15/73 (20.5%) | 14/64 (21.9%) | 1/9 (11.1%) | 0.675 |
Any fluoroquinolone | 41/129 (31.8%) | 26/72 (36.1%) | 22/63 (34.9%) | 4/9 (44.4%) | 0.714 |
Cotrimoxazole | 62/90 (68.9%) | 27/38 (71.1%) | 24/33 (72.7%) | 3/5 (60.0%) | 0.615 |
Fosfomycin | 1/52 (1.9%) | 1/44 (2.3%) | 1/38 (2.6%) | 0/6 (0%) | - |